GlassScriptPhysician profile
Maude Kaye
NPI 1831615772
$888.71
in general payments reported to CMS, 2019-2025
13 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $221 · 2023: $201 · 2024: $36.32 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $195.55 | 2021-2023 | Jornay Pm |
| Ucb, INC. | $157.83 | 2021-2023 | Briviact |
| Abbvie INC. | $124.88 | 2025 | |
| Supernus Pharmaceuticals, INC. | $110.84 | 2022-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $66.78 | 2021 | |
| Neurelis, INC. | $59.52 | 2021-2023 | Valtoco |
| Eisai INC. | $55.24 | 2021-2022 | |
| Corium, LLC | $25.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.77 | 2023 | |
| Azurity Pharmaceuticals, INC. | $22.48 | 2023 | Eprontia |
| Glaxosmithkline, LLC. | $18.42 | 2024 | Bexsero, Pediarix |
| Zogenix INC. | $16.40 | 2021 | |
| Biomarin Pharmaceutical INC. | $13.00 | 2023 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maude Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.